• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of cancer prevention: The official journal of the European Cancer Prevention Organisation (ECP) >Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance
【24h】

Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance

机译：不同剂量二甲双胍治疗6个月对中国糖耐量异常患者隐窝病灶的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This research was carried out to evaluate the chemopreventive effects of different doses of metformin treatment for 6 months on rectal aberrant crypt foci (ACF) in patients with impaired glucose tolerance (IGT). A total of 120 Chinese patients with IGT were enrolled and assigned randomly to a low-dose metformin group (n=30, metformin at 250mg/day), a middle-dose metformin group (n=30, metformin at 500mg/day), a high-dose metformin group (n=30, metformin at 1500mg/day), and a control (untreated with metformin) group (n=30). Each participant was followed for 6 months by protocol, and the number of ACF per patient in the above four groups was examined by magnifying colonoscopy before, and after 3 and 6 months of, treatment. The mean ACF numbers in both the middle-dose and the high-dose metformin groups were significantly decreased at 3 as well as 6 months of treatment, whereas they did not change in the low-dose metformin and the untreated groups. In the high-dose metformin group, BMI, waist circumference, fasting plasma glucose, homeostatic model assessment of insulin resistance index, and 2-h plasma glucose were significantly decreased. However, no such change was observed in the middle-dose metformin group. Changes in the ACF number correlated positively with changes in the homeostatic model assessment of insulin resistance (r=0.273, P=0.013), BMI (r=0.241, P=0.042), and 2-h plasma glucose (r=0.252, P=0.037), respectively, in the high-dose metformin group, but no such correlation was observed in the middle-dose metformin group. Metformin suppressed ACF formation in IGT patients in a dose-dependent manner, possibly through direct and indirect (attenuating insulin resistance) mechanisms. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
机译：进行了这项研究，以评估不同剂量的二甲双胍治疗6个月对糖耐量异常（IGT）患者的直肠异常隐窝灶（ACF）的化学预防作用。总共招募了120名中国IGT患者，并随机分为低剂量二甲双胍组（n = 30，二甲双胍为250mg /天），中剂量二甲双胍组（n = 30，二甲双胍为500mg /天），高剂量二甲双胍组（n = 30，二甲双胍剂量为1500mg /天）和对照组（未经二甲双胍治疗）组（n = 30）。按照方案对每位参与者进行6个月的随访，在治疗的3个月和6个月之后以及之后，通过放大结肠镜检查检查以上四组患者每人的ACF数量。在治疗的第3个月和第6个月，中剂量和高剂量二甲双胍组的平均ACF值均显着降低，而低剂量二甲双胍和未治疗组的平均ACF值没有变化。在大剂量二甲双胍组中，BMI，腰围，空腹血糖，胰岛素抵抗指数的稳态模型评估和2小时血糖均显着降低。但是，在中剂量二甲双胍组中未观察到这种变化。 ACF值的变化与胰岛素抵抗的稳态模型评估（r = 0.273，P = 0.013），BMI（r = 0.241，P = 0.042）和2小时血浆葡萄糖（r = 0.252，P）的变化呈正相关。 = 0.037）分别在大剂量二甲双胍组中出现，但在中剂量二甲双胍组中未观察到这种相关性。二甲双胍可能通过直接和间接（减弱的胰岛素抵抗）机制，以剂量依赖的方式抑制了IGT患者的ACF形成。 （C）2014 Wolters Kluwer Health垂直条Lippincott Williams＆Wilkins。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号